The Eagle-like effect of echinocandins: what’s in a name?

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Expert Review of Anti-Infective Therapy

• Publication date

  2013-10-18

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1586/14787210.2013.841543PMID 24134556
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibitory and Fungicidal Effects of Antifungal Drugs against Aspergillus Species in the Presence of Serum

  2013cited by this paper
• Pharmacokinetics of Anidulafungin in Critically Ill Patients with Candidemia/Invasive Candidiasis

  2013cited by this paper
• Effect of pH on the in vitro susceptibility of planktonic and biofilm‐grown Proteus mirabilis to the quinolone antimicrobials

  2013cited by this paper
• Time to positivity of blood culture can predict different Candida species instead of pathogen concentration in candidemia

  2013cited by this paper
• Activities of Systemically Administered Echinocandins against In Vivo Mature Candida albicans Biofilms Developed in a Rat Subcutaneous Model

  2013cited by this paper
• Immunological Aspects of Candida and Aspergillus Systemic Fungal Infections

  2013cited by this paper
• Pharmacokinetics of Caspofungin in Critically Ill Patients on Continuous Renal Replacement Therapy

  2013cited by this paper
• Effect of nikkomycin Z and 50% human serum on the killing activity of high-concentration caspofungin against Candida species using time-kill methodology

  2012cited by this paper
• In Vitro Activity of Calcineurin and Heat Shock Protein 90 Inhibitors against Aspergillus fumigatus Azole- and Echinocandin-Resistant Strains

  2012cited by this paper
• Heat Shock Protein 90 Is Required for Conidiation and Cell Wall Integrity in Aspergillus fumigatus

  2012cited by this paper
• Pharmacokinetics of Caspofungin in Two Patients with Burn Injuries

  2012cited by this paper
• Erratum to: Echinocandin antifungal drugs in fungal infections: a comparison

  2012cited by this paper
• Echinocandin Antifungal Drugs in Fungal Infections

  2012cited by this paper
• Pharmacokinetics of Micafungin in Pediatric Patients With Invasive Candidiasis and Candidemia

  2012cited by this paper
• Intracellular concentrations of micafungin in different cellular compartments of the peripheral blood.

  2012cited by this paper
• Laboratory diagnostics of invasive fungal infections: an overview with emphasis on molecular approach

  2012cited by this paper
• Plasma concentrations of caspofungin at two different dosage regimens in a patient with hepatic dysfunction

  2012cited by this paper
• Elevated Chitin Content Reduces the Susceptibility of Candida Species to Caspofungin

  2012cited by this paper
• Role of Innate Immune Receptors in Paradoxical Caspofungin Activity In Vivo in Preclinical Aspergillosis

  2012cited by this paper
• Intraocular Penetration of Micafungin in Patient with Candida albicans Endophthalmitis

  2011cited by this paper
• Diagnostic Issues, Clinical Characteristics, and Outcomes for Patients with Fungemia

  2011cited by this paper
• Five-Minute Exposure to Caspofungin Results in Prolonged Postantifungal Effects and Eliminates the Paradoxical Growth of Candida albicans

  2011cited by this paper
• Safety and Pharmacokinetics of Multiple‐Dose Anidulafungin in Infants and Neonates

  2011cited by this paper
• Paradoxical Effect of Caspofungin against Candida Bloodstream Isolates Is Mediated by Multiple Pathways but Eliminated in Human Serum

  2011cited by this paper
• Safety and Pharmacokinetics of Higher Doses of Caspofungin in Healthy Adult Participants

  2011cited by this paper
• In vitro assessment of the antifungal and paradoxical activity of different echinocandins against Candida tropicalis biofilms.

  2011cited by this paper
• Pharmacokinetics of Anidulafungin in Pleural Fluid during the Treatment of a Patient with Candida Empyema

  2011cited by this paper
• Detailed comparison of Candida albicans and Candida glabrata biofilms under different conditions and their susceptibility to caspofungin and anidulafungin.

  2011cited by this paper
• Pharmacokinetics of caspofungin in a critically ill patient with liver cirrhosis

  2011cited by this paper
• Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration.

  2011cited by this paper
• Micafungin Concentrations in the Plasma and Burn Eschar of Severely Burned Patients

  2011cited by this paper
• Transcriptional Regulation of Chitin Synthases by Calcineurin Controls Paradoxical Growth of Aspergillus fumigatus in Response to Caspofungin

  2010cited by this paper
• Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection:2009 update by the Infectious Diseases Society of America

  2010cited by this paper
• Changes in Cell Wall Synthesis and Ultrastructure during Paradoxical Growth Effect of Caspofungin on Four Different Candida Species

  2010cited by this paper
• Micafungin Concentrations from Brain Tissue and Pancreatic Pseudocyst Fluid

  2010cited by this paper
• In vivo studies with a Candida tropicalis isolate exhibiting paradoxical growth in vitro in the presence of high concentration of caspofungin

  2010cited by this paper
• Randomized Comparison of Safety and Pharmacokinetics of Caspofungin, Liposomal Amphotericin B, and the Combination of Both in Allogeneic Hematopoietic Stem Cell Recipients

  2010cited by this paper
• A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis.

  2009cited by this paper
• Bronchopulmonary Disposition of Intravenous Voriconazole and Anidulafungin Given in Combination to Healthy Adults

  2009cited by this paper
• The effects of an hsp90 inhibitor on the paradoxical effect.

  2009cited by this paper
• Paradoxical echinocandin activity: a limited in vitro phenomenon?

  2009cited by this paper
• Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America.

  2009cited by this paper
• In Vitro Susceptibility of Clinical Isolates of Aspergillus spp. to Anidulafungin, Caspofungin, and Micafungin: a Head-to-Head Comparison Using the CLSI M38-A2 Broth Microdilution Method

  2009cited by this paper
• In vitro analysis of the occurrence of a paradoxical effect with different echinocandins and Candida albicans biofilms.

  2009cited by this paper
• High caspofungin levels in alveolar cells of a lung transplant patient with suspected pulmonary aspergillosis.

  2009cited by this paper
• Paradoxical Growth of Candida dubliniensis Does Not Preclude In Vivo Response to Echinocandin Therapy

  2009cited by this paper
• Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation.

  2009cited by this paper
• Immunocompromised hosts: immunopharmacology of modern antifungals.

  2008cited by this paper
• Stimulation of Chitin Synthesis Rescues Candida albicans from Echinocandins

  2008cited by this paper
• Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis.

  2008cited by this paper
• In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth.

  2008cited by this paper
• Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis

  2008cited by this paper
• Pharmacokinetics and Safety of Caspofungin in Older Infants and Toddlers

  2008cited by this paper
• Differential Effects of Inhibiting Chitin and 1,3-β-d-Glucan Synthesis in Ras and Calcineurin Mutants of Aspergillus fumigatus

  2008cited by this paper
• Bronchopulmonary Disposition of Micafungin in Healthy Adult Volunteers

  2008cited by this paper
• Reference method for broth dilution antifungal susceptibility testing of filamentous fungi : Approved standard

  2008cited by this paper
• Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard

  2008cited by this paper
• Paradoxical Effect of Echinocandins across Candida Species In Vitro: Evidence for Echinocandin-Specific and Candida Species-Related Differences

  2007cited by this paper
• Plasma concentration of micafungin in patients with hematologic malignancies

  2007cited by this paper
• Paradoxical Growth Effect of Caspofungin Observed on Biofilms and Planktonic Cells of Five Different Candida Species

  2007cited by this paper
• Single‐ and Multiple‐Dose Administration of Caspofungin in Patients With Hepatic Insufficiency: Implications for Safety and Dosing Recommendations

  2007cited by this paper
• Attenuation of echinocandin activity at elevated concentrations: a review of the paradoxical effect

  2007cited by this paper
• Comparative In Vitro Pharmacodynamics of Caspofungin, Micafungin, and Anidulafungin against Germinated and Nongerminated Aspergillus Conidia

  2007cited by this paper
• Micafungin activity against Candida bloodstream isolates: effect of growth medium and susceptibility testing method.

  2007cited by this paper
• Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.

  2007cited by this paper
• Candida albicans and Candida dubliniensis Respond Differently to Echinocandin Antifungal Agents In Vitro

  2007cited by this paper
• Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit.

  2007cited by this paper
• The PKC, HOG and Ca2+ signalling pathways co‐ordinately regulate chitin synthesis in Candida albicans

  2007cited by this paper
• Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections.

  2006cited by this paper
• Concentration-Dependent Effects of Caspofungin on the Metabolic Activity of Aspergillus Species

  2006cited by this paper
• Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis.

  2006cited by this paper
• Steady-State Pharmacokinetics of Micafungin and Voriconazole after Separate and Concomitant Dosing in Healthy Adults

  2006cited by this paper
• Safety and Pharmacokinetics of Intravenous Anidulafungin in Children with Neutropenia at High Risk for Invasive Fungal Infections

  2006cited by this paper
• Assessment of the Paradoxical Effect of Caspofungin in Therapy of Candidiasis

  2006cited by this paper
• Escape of Candida from Caspofungin Inhibition at Concentrations above the MIC (Paradoxical Effect) Accomplished by Increased Cell Wall Chitin; Evidence for β-1,6-Glucan Synthesis Inhibition by Caspofungin

  2006cited by this paper
• The Pharmacokinetics and Safety of Micafungin, a Novel Echinocandin, in Premature Infants

  2006cited by this paper
• Pharmacokinetic and Maximum Tolerated Dose Study of Micafungin in Combination with Fluconazole versus Fluconazole Alone for Prophylaxis of Fungal Infections in Adult Patients Undergoing a Bone Marrow or Peripheral Stem Cell Transplant

  2005cited by this paper
• Hsp90 Potentiates the Rapid Evolution of New Traits: Drug Resistance in Diverse Fungi

  2005cited by this paper
• Assessment of the Safety and Pharmacokinetics of Anidulafungin When Administered With Cyclosporine

  2005cited by this paper
• Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis.

  2005cited by this paper
• Attenuation of the Activity of Caspofungin at High Concentrations against Candida albicans: Possible Role of Cell Wall Integrity and Calcineurin Pathways

  2005cited by this paper
• Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and Adolescents

  2005cited by this paper
• Antibacterial studies, DNA oxidative cleavage, and crystal structures of Cu(II) and Co(II) complexes with two quinolone family members, ciprofloxacin and enoxacin.

  2005cited by this paper
• Safety, Tolerability, and Pharmacokinetics of Micafungin (FK463) in Febrile Neutropenic Pediatric Patients

  2005cited by this paper
• Studies of the paradoxical effect of caspofungin at high drug concentrations.

  2005cited by this paper
• Paradoxical Effect of Caspofungin: Reduced Activity against Candida albicans at High Drug Concentrations

  2004cited by this paper
• Successful Micafungin (FK463) Treatment of Invasive Pulmonary Aspergillosis in a Patient with Acute Lymphoblastic Leukemia in a Phase II Study

  2004cited by this paper
• Uses and Limitations of the XTT Assay in Studies of Candida Growth and Metabolism

  2003cited by this paper
• The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy

  2003cited by this paper
• Caspofungin.

  2003cited by this paper
• In Vitro Pharmacodynamic Properties of Three Antifungal Agents against Preformed Candida albicans Biofilms Determined by Time-Kill Studies

  2002cited by this paper
• Antifungal Efficacy of Caspofungin (MK-0991) in Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits: Pharmacokinetics, Drug Disposition, and Relationship to Galactomannan Antigenemia

  2002cited by this paper
• Colorimetric Assay for Antifungal Susceptibility Testing ofAspergillus Species

  2001cited by this paper
• Biofilm Formation by the Fungal PathogenCandida albicans: Development, Architecture, and Drug Resistance

  2001cited by this paper
• The yeast cell-wall salvage pathway.

  2001cited by this paper
• Comparison of NCCLS and 3-(4,5-Dimethyl-2-Thiazyl)-2,5-Diphenyl-2H-Tetrazolium Bromide (MTT) Methods of In Vitro Susceptibility Testing of Filamentous Fungi and Development of a New Simplified Method

  2000cited by this paper
• Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents.

  2000cited by this paper
• Antifungal Efficacy, Safety, and Single-Dose Pharmacokinetics of LY303366, a Novel Echinocandin B, in Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits

  1998cited by this paper
• Comparison of a 2,3-Bis(2-Methoxy-4-Nitro-5-Sulfophenyl)-5-[(Phenylamino)Carbonyl]-2H-Tetrazolium Hydroxide (XTT) Colorimetric Method with the Standardized National Committee for Clinical Laboratory Standards Method of Testing Clinical Yeast Isolates for Susceptibility to Antifungal Agents

  1998cited by this paper
• Colorimetric susceptibility testing for Aspergillus fumigatus: comparison of menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide and Alamar blue tests

  1996cited by this paper

• First report of Candidozyma auris in Vietnam.

  2026cites this paper
• Antibacterial Potential of Lucilia sericata (Meigen, 1826) (Diptera: Calliphoridae) Maggot Excretions/Secretions in Presence of Human Tear Fluid

  2025cites this paper
• Prevalence and molecular basis of resistance to echinocandins among clinical Candida glabrata isolates in Guangdong province, China

  2025cites this paper
• Antifungal persistence: Clinical relevance and mechanisms

  2025cites this paper
• FIRST REPORT OF CANDIDA AURIS IN VIETNAM

  2025cites this paper
• In Vitro Susceptibility Tests in the Context of Antifungal Resistance: Beyond Minimum Inhibitory Concentration in Candida spp.

  2023cites this paper
• Sources of Antifungal Drugs

  2023cites this paper
• Aneuploidy underlies paradoxical growth of rezafungin and enables cross-tolerance to echinocandins in Candida albicans: Running title: Paradoxical growth potentiates drug tolerance via aneuploidy.

  2022cites this paper
• Echinocandins – structure, mechanism of action and use in antifungal therapy

  2022cites this paper
• Human and murine Cryptococcus neoformans infection selects for common genomic changes in an environmental isolate

  2022cites this paper
• Deciphering Candida auris Paradoxical Growth Effect (Eagle Effect) in Response to Echinocandins.

  2022cites this paper
• Molecular characterisation of Candida auris isolates from immunocompromised patients in a tertiary‐care hospital in Kuwait reveals a novel mutation in FKS1 conferring reduced susceptibility to echinocandins

  2021cites this paper
• Antifungal Susceptibility Testing: A Primer for Clinicians

  2021cites this paper
• Candida auris Identification and Rapid Antifungal Susceptibility Testing Against Echinocandins by MALDI-TOF MS

  2019cites this paper
• Minimal Inhibitory Concentration (MIC)-Phenomena in Candida albicans and Their Impact on the Diagnosis of Antifungal Resistance

  2019cites this paper
• Antimicrobial Therapy in the Context of the Damage-Response Framework: the Prospect of Optimizing Therapy by Reducing Host Damage

  2019cites this paper
• Résistance des micromycètes aux antifongiques

  2019cites this paper
• The Eagle Effect and Antibiotic-Induced Persistence: Two Sides of the Same Coin?

  2019cites this paper
• In vitro antibacterial effects of statins against bacterial pathogens causing skin infections

  2018cites this paper
• Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris

  2018cites this paper
• Pharmacokinetics of extended dose intervals of micafungin in haematology patients: optimizing antifungal prophylaxis

  2018cites this paper
• Fungal persister cells: The basis for recalcitrant infections?

  2018cites this paper
• Combined Effect of Platelets and Anidulafungin against Aspergillus fumigatus Infections

  2017cites this paper
• Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients

  2017cites this paper
• Echinocandins in antifungal pharmacotherapy

  2017cites this paper
• Frequency of the paradoxical effect measured using EUCAST with 1 micafungin, anidulafungin, and caspofungin against Candida spp. isolates 2 causing candidemia 3

  2016cites this paper
• The Paradoxical Effect of Echinocandins in Aspergillus fumigatus Relies on Recovery of the β-1,3-Glucan Synthase Fks1

  2016cites this paper
• Frequency of the Paradoxical Effect Measured Using the EUCAST Procedure with Micafungin, Anidulafungin, and Caspofungin against Candida Species Isolates Causing Candidemia

  2016cites this paper
• Testing of the antifungal activity of oleylphosphocholine on Candida albicans planktonic cells and biofilms developed in vitro and in vivo in a subcutaneous biofilm model

  2015cites this paper
• Antifungal pharmacokinetics and pharmacodynamics.

  2015cites this paper
• A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients.

  2014cites this paper
• Antifungal Pharmacokinetics and Pharmacodynamics Subject Collection Human Fungal Pathogens Pneumocystis

  2014cites this paper